Roche's Oral Breast Cancer Pill Giredestrant Lands FDA Approval
The FDA has cleared Roche's Wilserdly (giredestrant), an oral drug for advanced breast cancer that has stopped responding to hormone therapy. In a phase III trial it cut the risk of disease progression or death by 62%. India is watching — but the drug needs its own regulatory green light first.
- Original source: outlookindia.com.
- The source published it on Nov 20, 2026 at 4:01 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
Roche now has US Food and Drug Administration approval for Wilserdly (giredestrant), an oral treatment given alongside everolimus. The green light covers adults with oestrogen receptor (ER)-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease no longer responds to hormone-based therapy. It targets a group of patients who typically run short of options once existing treatments stop working.
The headline number comes from the global phase III evERA trial. In patients whose tumours carried ESR1 mutations, the giredestrant combination reduced the risk of disease progression or death by 62% compared with standard endocrine therapy plus everolimus. That matters because ESR1 mutations are estimated to show up in up to 40% of people with hormone receptor-positive metastatic breast cancer, and they are a leading reason hormone treatments eventually fail.
Giredestrant is an oral selective oestrogen receptor degrader (SERD): it blocks the oestrogen receptor and triggers its breakdown, cutting off signals that feed certain breast cancer cells. Everolimus attacks a separate growth pathway, so the pair hits two mechanisms behind tumour progression and resistance. The pill form means patients can take treatment at home instead of scheduling injections, though medical supervision, monitoring and side-effect management are still required.
India is not covered by the US decision. Wilserdly will need its own Indian regulatory clearances before it can be marketed there for this use, and how far it spreads will hinge on price, the availability of ESR1 mutation testing and access to specialist oncology services. Breast cancer is the most common cancer among Indian women, with nearly 2.39 lakh new cases projected for 2025 by the National Cancer Registry Programme. For families already stretched by advanced cancer costs, affordability could decide everything.
One caveat: this is not a cure. The trial showed a significant delay in disease progression, not proof that the treatment wipes out the disease or extends overall survival. Roche is also waiting on a separate FDA ruling for giredestrant as an adjuvant therapy in early-stage ER-positive, HER2-negative breast cancer, with a decision expected by November 30, 2026 — a verdict that would push the drug into post-surgery care aimed at keeping cancer from returning.
TopicsRoche · giredestrant · Wilserdly · FDA · everolimus · India's National Cancer Registry Programme · ESR1
Source: outlookindia.com
Written by AI from verified reporting.
More stories
- Health & science medicalxpress.com Caught by @ajayy30 0 viewsGuinea Pig Ears Upend the Nobel-Winning Map of How We Hear
- Health & science phys.org Caught by @ajayy30 0 viewsLopsided galaxies are shaped from within, catalog of 606 suggests
- Health & science sciencedaily.com Caught by @ajayy30 0 viewsMoon dust 3D-printed into LEGO-style bricks for future lunar bases
- Health & science medtechdive.com 1 viewZimmer files FDA 510(k) for Monogram knee robot, eyes 2027 launch

